Proliferative diabetic retinopathy (PDR) represents the most advanced, vision-threatening stage of diabetic eye disease. It affects approximately 7% of adults with diabetes globally, and without timely intervention, it frequently leads to severe visual impairment or blindness. The underlying driver of this condition is a dysregulated wound-healing response within the retina, orchestrated by a family of signaling proteins known as growth factors. Understanding how these molecules trigger the formation of abnormal new blood vessels—a process called neovascularization—has revolutionized the management of PDR over the past two decades. This article delves into the specific growth factors implicated in PDR development, their pathological roles, and how this knowledge directly informs current and emerging treatment strategies.

What Are Growth Factors?

Growth factors are naturally occurring proteins or steroid hormones that bind to specific receptors on the surface of target cells, initiating a cascade of intracellular signals that regulate cell proliferation, differentiation, migration, and survival. In the healthy eye, these molecules are tightly controlled, playing essential roles in embryonic development, wound healing, and maintenance of the ocular vasculature. However, in the diabetic retina, prolonged metabolic stress disrupts the normal balance between pro-angiogenic (promoting vessel formation) and anti-angiogenic factors. This imbalance shifts the micro-environment toward an angiogenic state, where growth factors such as vascular endothelial growth factor (VEGF) are overexpressed. The resulting uncontrolled neovascularization is the hallmark of PDR.

Growth factors are not limited to VEGF; a complex network of multiple proteins and their co-receptors contributes to the full pathological picture. These include platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), insulin-like growth factor-1 (IGF-1), hepatocyte growth factor (HGF), and others. Each interacts with VEGF and with each other, creating a system that can amplify and sustain abnormal vessel growth. Researchers continue to map these interactions to identify new therapeutic targets.

Pathophysiology: How Growth Factors Drive PDR

From Hyperglycemia to Retinal Ischemia

The development of PDR is a multi-step process that begins with chronic hyperglycemia. Sustained high blood glucose levels damage the retinal capillaries, leading to pericyte loss, basement membrane thickening, and endothelial cell dysfunction. Over time, these microvascular changes cause capillary occlusion and non-perfusion, resulting in areas of the retina that are starved of oxygen (hypoxia). The severity and extent of retinal ischemia correlate directly with the risk of progression to PDR.

When retinal neurons and glial cells (including Muller cells) sense hypoxic stress, they produce hypoxia-inducible factor-1 alpha (HIF-1α). This transcription factor upregulates the expression of multiple pro-angiogenic genes, most notably the gene encoding VEGF. VEGF is the primary growth factor responsible for stimulating endothelial cell proliferation and new vessel formation. In the diabetic retina, VEGF levels become chronically elevated, both in the vitreous and within the retinal tissue.

Neovascularization and the Fragile Vessels

The new blood vessels induced by VEGF are structurally abnormal. They are often tortuous, lack smooth muscle coverage, and have leaky endothelial junctions. These fragile vessels grow along the inner surface of the retina and can extend into the vitreous cavity, where they are prone to hemorrhage. Additionally, these vessels are accompanied by fibrous tissue that may contract, causing tractional retinal detachment. The end result is vision loss from vitreous hemorrhage, retinal detachment, or neovascular glaucoma. Thus, growth factors are not only the trigger for vessel formation but also determine the vessel quality and the secondary complications of PDR.

Key Growth Factors Involved in PDR

Vascular Endothelial Growth Factor (VEGF)

VEGF, particularly the VEGF-A isoform, is the central and most potent pro-angiogenic factor in PDR. It binds to two main receptors (VEGFR-1 and VEGFR-2) on endothelial cells, activating signaling pathways that promote cell division, migration, and tube formation. Clinical studies have shown that intraocular VEGF levels are dramatically elevated in eyes with active PDR compared to non-proliferative diabetic retinopathy or control eyes. The strong association between VEGF levels and disease activity has made VEGF the primary target for current pharmacologic treatments. Anti-VEGF agents such as ranibizumab (Lucentis), aflibercept (Eylea), and bevacizumab (Avastin) can rapidly regress neovascularization and reduce vitreous hemorrhage risk.

Platelet-Derived Growth Factor (PDGF)

PDGF, especially the PDGF-B isoform, is produced by endothelial cells, pericytes, and macrophages. It binds to PDGF receptors (PDGFR-α and PDGFR-β) on pericytes and smooth muscle cells. In normal vessel maturation, PDGF recruits pericytes to wrap around newly formed endothelial tubes, providing stability and regulating blood flow. However, in PDR, the PDGF system is dysregulated. The presence of PDGF promotes the coverage of new vessels with pericytes, making them more resistant to regression by anti-VEGF therapy alone. This explains why some PDR patients require repeated injections or combination treatments. Preclinical models also suggest that targeting both VEGF and PDGF may lead to more sustained vessel involution.

Basic Fibroblast Growth Factor (bFGF, FGF-2)

bFGF is a member of the fibroblast growth factor family and is a potent mitogen for endothelial cells. It is stored in the extracellular matrix and released during tissue injury or hypoxia. In the diabetic retina, bFGF levels are elevated in the vitreous and retinal tissues. bFGF works synergistically with VEGF to promote endothelial cell proliferation and tube formation. It also stimulates the proliferation of retinal pigment epithelial cells and glial cells, contributing to the fibrous component of PDR. Because bFGF can bypass VEGF receptor blockade in some cases, it may play a role in anti-VEGF treatment resistance.

Insulin-Like Growth Factor-1 (IGF-1)

IGF-1 is a hormone that mediates many effects of growth hormone. It is produced locally in the retina and also reaches the eye from the systemic circulation. In the context of PDR, IGF-1 acts as a permissive factor for VEGF-driven neovascularization. Animal models have demonstrated that systemic infusion of IGF-1 can exacerbate retinal neovascularization, and blockade of IGF-1 receptors reduces the angiogenic response. Additionally, IGF-1 promotes survival of endothelial cells, making them less susceptible to apoptosis. Serum levels of IGF-1 are often altered in diabetes, and this axis is being explored as an adjunctive therapeutic target.

Hepatocyte Growth Factor (HGF)

HGF, also known as scatter factor, is produced by mesenchymal cells and activates the c-Met receptor on epithelial and endothelial cells. HGF has both angiogenic and anti-apoptotic properties. Vitreous levels of HGF are significantly elevated in PDR patients and correlate with the degree of vitreous hemorrhage. HGF can promote endothelial cell migration and tube formation independently of VEGF, and it may contribute to the persistent neovascularization seen in some eyes despite anti-VEGF therapy. Targeting the HGF/c-Met axis could offer a complementary strategy for recalcitrant PDR.

Clinical Implications of Growth Factor Biology

Anti-VEGF Therapy: The Cornerstone

The discovery of VEGF's central role in PDR led directly to the development of intraocular anti-VEGF injections, which have become the standard first-line treatment for patients with active PDR. Multiple randomized clinical trials (e.g., DRCR.net Protocol S) have shown that anti-VEGF therapy (ranibizumab) is non-inferior to panretinal photocoagulation (PRP) for preventing vision loss and may even offer superior outcomes in reducing diabetic macular edema. The main advantages of anti-VEGF therapy include rapid regression of neovascularization, lower risk of peripheral visual field loss, and less impact on night vision compared to PRP. However, the need for repeated injections (often monthly or bimonthly) and the burden of follow-up visits remain significant limitations.

Combination and Multi-Target Approaches

Given the redundancy of angiogenic factors, researchers have explored combining anti-VEGF agents with other modalities. One promising approach is the addition of an anti-PDGF agent to destabilize newly formed vessels. A phase II trial of a combined anti-VEGF/anti-PDGF aptamer (Fovista) showed some anatomical benefit in exudative age-related macular degeneration, but results in diabetic retinopathy have been more modest. Another strategy is to use broad-spectrum inhibitors such as tyrosine kinase inhibitors (e.g., pazopanib, sunitinib) that block multiple growth factor receptors. Oral or topical administration of these drugs is under investigation, although systemic side effects remain a concern.

Laser and Surgical Considerations

Despite the success of pharmacotherapy, panretinal photocoagulation remains an important tool, especially in eyes that are poor candidates for injections (e.g., due to cost, compliance, or recurrent vitreous hemorrhage). PRP works by destroying ischemic retinal tissue, thereby reducing the production of VEGF and other growth factors. However, it also causes collateral damage to the retina, leading to permanent loss of peripheral and night vision. Vitrectomy is indicated for persistent vitreous hemorrhage or tractional retinal detachment. During surgery, removal of the vitreous gel (which contains high concentrations of growth factors) can rapidly lower the angiogenic drive. Post-vitrectomy, anti-VEGF injections are often used to prevent recurrent bleeding or to treat residual neovascularization.

Future Directions: Beyond VEGF

Targeting HIF-1α and the Hypoxic Response

Because HIF-1α is the master regulator of the angiogenesis program, pharmaceutical inhibition of HIF-1α could reduce the expression of multiple downstream growth factors simultaneously. Small-molecule inhibitors of HIF-1α are being studied in oncology and are beginning to enter preclinical eye research. Another strategy is to upregulate the body's own anti-angiogenic factors. For example, pigment epithelium-derived factor (PEDF) is a natural inhibitor of angiogenesis that is reduced in the diabetic retina. Gene therapy or protein replacement aimed at restoring PEDF levels is an active area of investigation.

Gene Therapy and Long-Acting Delivery

Gene therapy offers the promise of long-term, perhaps even one-time, treatment by delivering a transgene that encodes an anti-VEGF protein or a soluble decoy receptor. AAV-based vectors injected into the vitreous or subretinal space have shown durable suppression of neovascularization in animal models and are now in early clinical trials. Sustained-release drug delivery systems (e.g., the Port Delivery System with ranibizumab) have recently been approved, reducing injection frequency to only a few times per year. Future implants that release combination drugs could further improve patient convenience and outcomes.

Precision Medicine and Biomarkers

Not all PDR patients respond equally to anti-VEGF therapy. Genetic variations in the VEGF gene or other pathway components may influence drug response. Studies are identifying single-nucleotide polymorphisms that predict which patients need higher treatment burdens. Additionally, proteomic analysis of vitreous samples may eventually guide individualized combination therapy. The goal is to move from a one-size-fits-all anti-VEGF regimen to a personalized approach that tailors treatment to the specific growth factor profile of each patient's eye.

Conclusion

Growth factors are the central players in the pathogenesis of proliferative diabetic retinopathy. They transform a state of retinal ischemia into a destructive process of neovascularization, vitreous hemorrhage, and tractional detachment. A deep understanding of the roles of VEGF, PDGF, bFGF, IGF-1, and HGF has already yielded highly effective therapies that save sight. However, the complexity of the angiogenic network means that targeting a single factor, even the dominant force of VEGF, is not always sufficient. The future of PDR management lies in combination approaches—whether through multi-target drugs, gene therapy, or personalized biomarker-driven treatments—that neutralize multiple pathways simultaneously. For clinicians and researchers, the growth factor story remains one of the most compelling chapters in ophthalmic medicine, with new therapeutic horizons continually emerging.

External Resources for Further Reading